Aurinia CLO sells 11,939 shares at $15.95

AUPH’s Chief Legal Officer reported an automatic sale of shares to cover taxes on vested performance stock units, leaving a sizable remaining direct stake.

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. (AUPH) reported that Chief Legal Officer Stephen P. Robertson sold 11,939 shares of common stock on September 10, 2026 at a weighted average price of about $15.95 per share, with trades between $15.95 and $15.96. The shares were automatically sold solely to cover tax withholding obligations arising from the vesting of Performance Stock Units related to a February 28, 2025 performance award, and Robertson now holds 588,848 shares directly.

Insider Trade Summary

Net Seller: 11,939 shares

Net Sell 1 txn

Insider Robertson Stephen P.

Role Chief Legal Officer

Sold 11,939 shs ($190K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	11,939	$15.95	$190K

Holdings After Transaction: Common Stock — 588,848 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award.
2. F2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 11,939 shares Weighted average sale price: $15.95 per share Post-transaction holdings: 588,848 shares +2 more

5 metrics

Shares sold 11,939 shares Common stock sold on September 10, 2026 to cover tax withholding

Weighted average sale price $15.95 per share Weighted average, with trades from $15.95 to $15.96 per share

Post-transaction holdings 588,848 shares Direct ownership after the September 10, 2026 sale

Net shares sold 11,939 shares Net selling activity reported in this Form 4

Performance award date February 28, 2025 PSU award whose vesting led to tax-withholding sale

Key Terms

Performance Stock Units (PSUs), tax withholding obligations, weighted average price

3 terms

Performance Stock Units (PSUs) financial

"vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award"

Performance stock units (PSUs) are a form of executive or employee pay that promise company shares only if pre-set performance goals are met over a defined period; think of them as a bonus paid in stock that arrives only when the company hits agreed targets. Investors watch PSUs because they affect the number of shares outstanding (dilution) and reveal how management’s pay is tied to financial or operational results, aligning incentives with shareholder outcomes.

tax withholding obligations financial

"shares automatically sold to cover tax withholding obligations in connection with the vesting"

weighted average price financial

"The price in column 4 is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AUPH report for Chief Legal Officer Stephen P. Robertson?

Aurinia Pharmaceuticals reported that Stephen P. Robertson sold 11,939 shares of common stock on September 10, 2026. The sale was an automatic transaction to cover tax withholding obligations tied to the vesting of Performance Stock Units from a February 28, 2025 performance award.

Was the AUPH insider sale by Stephen P. Robertson part of a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 plan was reported for this transaction. The footnotes describe the sale as an automatic sale to cover tax withholding obligations in connection with the vesting of Performance Stock Units.

What price did Stephen P. Robertson receive for the AUPH shares sold?

The reported weighted average sale price was about $15.95 per share, with individual trades executed in a range from $15.95 to $15.96 per share. The insider undertook to provide full breakdowns of the share amounts at each price upon request.

How many AUPH shares does Stephen P. Robertson hold after this transaction?

Following the September 10, 2026 sale, Stephen P. Robertson directly holds 588,848 shares of Aurinia Pharmaceuticals Inc. common stock. This figure is reported as his direct ownership after the automatic sale for tax withholding.

Why were the 11,939 AUPH shares sold by Stephen P. Robertson?

The 11,939 shares were automatically sold to satisfy tax withholding obligations triggered by the vesting of Performance Stock Units (PSUs) related to a February 28, 2025 performance award. The sale was not characterized as a discretionary open-market liquidation.

How many AUPH shares in total did Stephen P. Robertson sell in this Form 4 filing?

The Form 4 shows that Stephen P. Robertson sold a total of 11,939 shares of Aurinia Pharmaceuticals Inc. common stock in this reported transaction. All of these shares were sold on September 10, 2026 to cover tax withholding obligations upon PSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:26 PM Accepted by SEC EDGAR 09/11/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robertson Stephen P.

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		S		11,939(1)	D	$15.95(2)	588,848	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award.

2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Stephen P. Robertson	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)